Report Detail

Pharma & Healthcare Global Non-oncology Biopharmaceuticals Market Size, Status and Forecast 2019-2025

  • RnM3425505
  • |
  • 16 May, 2019
  • |
  • Global
  • |
  • 100 Pages
  • |
  • QYResearch
  • |
  • Pharma & Healthcare

Biopharmaceutical, also known as a biologic (al) medical product, biological, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semi synthesized from biological sources. Different from totally synthesized pharmaceuticals, they include vaccines, blood, blood components, allergenic, somatic cells, gene therapies, tissues, recombinant therapeutic protein, and living cells used in cell therapy. Biologics can be composed of sugars, proteins, or nucleic acids or complex combinations of these substances, or may be living cells or tissues. They (or their precursors or components) are isolated from living sources—human, animal, plant, fungal, or microbial. This report studies Non-oncology biopharmaceutical which are the drugs that are used in the treatment of various diseases rather than cancer.
In 2018, the global Non-oncology Biopharmaceuticals market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Non-oncology Biopharmaceuticals status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Non-oncology Biopharmaceuticals development in United States, Europe and China.

The key players covered in this study
Roche
Sanofi
Johnson & Johnson
Pfizer
Novo Nordisk
Novartis
Merck
Teva
Eli Lilly
Bristol-Myers Squibb
GlaxoSmithKline
UCB Pharma
Amgen
AbbVie
Takeda
AstraZeneca
Mylan
LEO Pharma
Boehringer Ingelheim
Alexion Pharmaceuticals
Elusys Therapeutics
Swedish Orphan Biovitrum
Biogen

Market segment by Type, the product can be split into
Biologics
Biosimilars

Market segment by Application, split into
Immunology
Endocrinology
Others

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Non-oncology Biopharmaceuticals status, future forecast, growth opportunity, key market and key players.
To present the Non-oncology Biopharmaceuticals development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Non-oncology Biopharmaceuticals are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.


Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Non-oncology Biopharmaceuticals Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Biologics
      • 1.4.3 Biosimilars
    • 1.5 Market by Application
      • 1.5.1 Global Non-oncology Biopharmaceuticals Market Share by Application (2014-2025)
      • 1.5.2 Immunology
      • 1.5.3 Endocrinology
      • 1.5.4 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Non-oncology Biopharmaceuticals Market Size
    • 2.2 Non-oncology Biopharmaceuticals Growth Trends by Regions
      • 2.2.1 Non-oncology Biopharmaceuticals Market Size by Regions (2014-2025)
      • 2.2.2 Non-oncology Biopharmaceuticals Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Challenges
      • 2.3.4 Porter’s Five Forces Analysis

    3 Market Share by Key Players

    • 3.1 Non-oncology Biopharmaceuticals Market Size by by Players
      • 3.1.1 Global Non-oncology Biopharmaceuticals Revenue by by Players (2014-2019)
      • 3.1.2 Global Non-oncology Biopharmaceuticals Revenue Market Share by by Players (2014-2019)
      • 3.1.3 Global Non-oncology Biopharmaceuticals Market Concentration Ratio (CR5 and HHI)
    • 3.2 Non-oncology Biopharmaceuticals Key Players Head office and Area Served
    • 3.3 Key Players Non-oncology Biopharmaceuticals Product/Solution/Service
    • 3.4 Date of Enter into Non-oncology Biopharmaceuticals Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Non-oncology Biopharmaceuticals Market Size by Type (2014-2019)
    • 4.2 Global Non-oncology Biopharmaceuticals Market Size by Application (2014-2019)

    5 United States

    • 5.1 United States Non-oncology Biopharmaceuticals Market Size (2014-2019)
    • 5.2 Non-oncology Biopharmaceuticals Key Players in United States
    • 5.3 United States Non-oncology Biopharmaceuticals Market Size by Type
    • 5.4 United States Non-oncology Biopharmaceuticals Market Size by Application

    6 Europe

    • 6.1 Europe Non-oncology Biopharmaceuticals Market Size (2014-2019)
    • 6.2 Non-oncology Biopharmaceuticals Key Players in Europe
    • 6.3 Europe Non-oncology Biopharmaceuticals Market Size by Type
    • 6.4 Europe Non-oncology Biopharmaceuticals Market Size by Application

    7 China

    • 7.1 China Non-oncology Biopharmaceuticals Market Size (2014-2019)
    • 7.2 Non-oncology Biopharmaceuticals Key Players in China
    • 7.3 China Non-oncology Biopharmaceuticals Market Size by Type
    • 7.4 China Non-oncology Biopharmaceuticals Market Size by Application

    8 Japan

    • 8.1 Japan Non-oncology Biopharmaceuticals Market Size (2014-2019)
    • 8.2 Non-oncology Biopharmaceuticals Key Players in Japan
    • 8.3 Japan Non-oncology Biopharmaceuticals Market Size by Type
    • 8.4 Japan Non-oncology Biopharmaceuticals Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Non-oncology Biopharmaceuticals Market Size (2014-2019)
    • 9.2 Non-oncology Biopharmaceuticals Key Players in Southeast Asia
    • 9.3 Southeast Asia Non-oncology Biopharmaceuticals Market Size by Type
    • 9.4 Southeast Asia Non-oncology Biopharmaceuticals Market Size by Application

    10 India

    • 10.1 India Non-oncology Biopharmaceuticals Market Size (2014-2019)
    • 10.2 Non-oncology Biopharmaceuticals Key Players in India
    • 10.3 India Non-oncology Biopharmaceuticals Market Size by Type
    • 10.4 India Non-oncology Biopharmaceuticals Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Non-oncology Biopharmaceuticals Market Size (2014-2019)
    • 11.2 Non-oncology Biopharmaceuticals Key Players in Central & South America
    • 11.3 Central & South America Non-oncology Biopharmaceuticals Market Size by Type
    • 11.4 Central & South America Non-oncology Biopharmaceuticals Market Size by Application

    12 International Players Profiles

    • 12.1 Roche
      • 12.1.1 Roche Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Non-oncology Biopharmaceuticals Introduction
      • 12.1.4 Roche Revenue in Non-oncology Biopharmaceuticals Business (2014-2019)
      • 12.1.5 Roche Recent Development
    • 12.2 Sanofi
      • 12.2.1 Sanofi Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Non-oncology Biopharmaceuticals Introduction
      • 12.2.4 Sanofi Revenue in Non-oncology Biopharmaceuticals Business (2014-2019)
      • 12.2.5 Sanofi Recent Development
    • 12.3 Johnson & Johnson
      • 12.3.1 Johnson & Johnson Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Non-oncology Biopharmaceuticals Introduction
      • 12.3.4 Johnson & Johnson Revenue in Non-oncology Biopharmaceuticals Business (2014-2019)
      • 12.3.5 Johnson & Johnson Recent Development
    • 12.4 Pfizer
      • 12.4.1 Pfizer Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 Non-oncology Biopharmaceuticals Introduction
      • 12.4.4 Pfizer Revenue in Non-oncology Biopharmaceuticals Business (2014-2019)
      • 12.4.5 Pfizer Recent Development
    • 12.5 Novo Nordisk
      • 12.5.1 Novo Nordisk Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 Non-oncology Biopharmaceuticals Introduction
      • 12.5.4 Novo Nordisk Revenue in Non-oncology Biopharmaceuticals Business (2014-2019)
      • 12.5.5 Novo Nordisk Recent Development
    • 12.6 Novartis
      • 12.6.1 Novartis Company Details
      • 12.6.2 Company Description and Business Overview
      • 12.6.3 Non-oncology Biopharmaceuticals Introduction
      • 12.6.4 Novartis Revenue in Non-oncology Biopharmaceuticals Business (2014-2019)
      • 12.6.5 Novartis Recent Development
    • 12.7 Merck
      • 12.7.1 Merck Company Details
      • 12.7.2 Company Description and Business Overview
      • 12.7.3 Non-oncology Biopharmaceuticals Introduction
      • 12.7.4 Merck Revenue in Non-oncology Biopharmaceuticals Business (2014-2019)
      • 12.7.5 Merck Recent Development
    • 12.8 Teva
      • 12.8.1 Teva Company Details
      • 12.8.2 Company Description and Business Overview
      • 12.8.3 Non-oncology Biopharmaceuticals Introduction
      • 12.8.4 Teva Revenue in Non-oncology Biopharmaceuticals Business (2014-2019)
      • 12.8.5 Teva Recent Development
    • 12.9 Eli Lilly
      • 12.9.1 Eli Lilly Company Details
      • 12.9.2 Company Description and Business Overview
      • 12.9.3 Non-oncology Biopharmaceuticals Introduction
      • 12.9.4 Eli Lilly Revenue in Non-oncology Biopharmaceuticals Business (2014-2019)
      • 12.9.5 Eli Lilly Recent Development
    • 12.10 Bristol-Myers Squibb
      • 12.10.1 Bristol-Myers Squibb Company Details
      • 12.10.2 Company Description and Business Overview
      • 12.10.3 Non-oncology Biopharmaceuticals Introduction
      • 12.10.4 Bristol-Myers Squibb Revenue in Non-oncology Biopharmaceuticals Business (2014-2019)
      • 12.10.5 Bristol-Myers Squibb Recent Development
    • 12.11 GlaxoSmithKline
    • 12.12 UCB Pharma
    • 12.13 Amgen
    • 12.14 AbbVie
    • 12.15 Takeda
    • 12.16 AstraZeneca
    • 12.17 Mylan
    • 12.18 LEO Pharma
    • 12.19 Boehringer Ingelheim
    • 12.20 Alexion Pharmaceuticals
    • 12.21 Elusys Therapeutics
    • 12.22 Swedish Orphan Biovitrum
    • 12.23 Biogen

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Regions
    • 13.2 United States
    • 13.3 Europe
    • 13.4 China
    • 13.5 Japan
    • 13.6 Southeast Asia
    • 13.7 India
    • 13.8 Central & South America
    • 13.9 Market Size Forecast by Product (2019-2025)
    • 13.10 Market Size Forecast by Application (2019-2025)

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 12.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      Summary:
      Get latest Market Research Reports on Non-oncology Biopharmaceuticals . Industry analysis & Market Report on Non-oncology Biopharmaceuticals is a syndicated market report, published as Global Non-oncology Biopharmaceuticals Market Size, Status and Forecast 2019-2025. It is complete Research Study and Industry Analysis of Non-oncology Biopharmaceuticals market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

      Last updated on

      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      $3,900.00
      $5,850.00
      $7,800.00
      3,116.10
      4,674.15
      6,232.20
      3,638.70
      5,458.05
      7,277.40
      606,645.00
      909,967.50
      1,213,290.00
      324,987.00
      487,480.50
      649,974.00
      Credit card Logo

      Related Reports


      Reason to Buy

      Request for Sample of this report